About: Tackling COVID-19 Pandemic through Nanocoatings: Confront and Exactitude

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tackling COVID-19 Pandemic through Nanocoatings: Confront and Exactitude Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tackling COVID-19 Pandemic through Nanocoatings: Confront and Exactitude
Creator	Gupta, Vijai Kumar Gupta, Vijai Mishra, Yogendra Mishra, Y Thakur, Vijay Gupta, V Kumar Rai, Pradeep Rai, P Rai, Pradeep Thakur, V Usmani, Z Usmani, Zeba
source	Elsevier; PMC
abstract	Abstract After the eruption of the most deadly influenza flu pandemic in 1918, also known as Spanish flu, infected about 500 million people with a death toll of approximately 50 million globally, the second most devastating pandemic flue emerged in December 2019 at Wuhan (Hubei Province) of China. This viral disease caused by a novel coronavirus SARS-COV-2 was named COVID-19 by World Health Organization (WHO). The COVID-19 virus affected 213 countries globally with 5.6 million cases and 353,373 deaths as of May 28, 2020 [1] (Fig. 1). Still, there is no promising solution known to tackle this severe epidemic disease worldwide. Protecting the global population from COVID-19 we must follow three steps – early detection, monitoring, and treatment. At the same time, it is important to follow WHO guidelines on preventive measures. Many countries have restricted the movement of people completely and lockdown enforced to maintain social distancing. But lockdown alone is insufficient to prevent resurgence, can upend economies and roil society. People need to step out to perform essential tasks and may get exposed to this deadly virus. Learnings from previous outbreaks suggest the usage of nanotechnology as an important avenue to develop antiviral drugs and materials. So, to effectively minimize the acquired infection of COVID-19 in public places like hospitals, transport, schools, worship places, stores, malls, etc. antimicrobial nanocoatings at these places and development of targeted antiviral drugs through capped nanoparticles will be a major effective option to tackle the spread of this disease.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1016/j.crgsc.2020.100011
has license	els-covid
sha1sum (hex)	20b74039ae20e4dfae0a66ff5caa3e00484af24d
schema:url	https://doi.org/10.1016/j.crgsc.2020.100011
resource representing a document's title	Tackling COVID-19 Pandemic through Nanocoatings: Confront and Exactitude
has PubMed Central identifier	PMC7346813
resource representing a document's body	covid:20b74039ae20e4dfae0a66ff5caa3e00484af24d#body_text
is schema:about of	named entity 'APPROXIMATELY' named entity 'PANDEMIC' named entity '500' named entity 'MILLION' named entity 'globally' named entity '50 million' named entity 'influenza' named entity 'flu pandemic' named entity 'COVID-19 Pandemic' named entity 'COVID' named entity 'antiviral drugs' named entity 'enveloped viruses' named entity 'virus' named entity 'virucidal' named entity 'subclinical infection' named entity 'pathogenic viruses' named entity 'hypertension' named entity 'polio' named entity 'antiviral drugs' named entity 'clinical trials' named entity 'antiviral drugs' named entity 'viruses' named entity 'lung' named entity 'Hepatitis' named entity 'pneumonia' named entity 'WHO' named entity 'lipid envelope' named entity 'Dengue' named entity 'antibodies' named entity 'infection' named entity 'viruses' named entity 'ACE2' named entity 'China' named entity 'vaccines' named entity 'flu' named entity 'shortness of breath' named entity 'TMPRSS2' named entity 'diabetes' named entity 'Hydroxychloroquine' named entity 'influenza H1N1' named entity 'social distancing' named entity 'incubation period' named entity 'dengue' named entity 'nanotechnology' named entity 'chickenpox' named entity 'receptor proteins' named entity 'human beings' named entity 'COVID-19 Pandemic' named entity 'nanoparticles' named entity 'antimicrobial' named entity 'infection' named entity 'inside the cell' named entity 'epidemiological' named entity 'herd immunity' named entity 'RNA' named entity 'type 2' named entity 'global population' named entity 'antimicrobial' named entity 'micro-organisms' named entity 'breathing difficulties' named entity 'Yellow fever' named entity 'viral shedding' named entity 'mumps' named entity 'vaccines' named entity 'TMPRSS2' named entity 'Chloroquine phosphate' named entity 'measles' named entity 'antiviral drugs' named entity 'COVID' named entity 'preventive measures' named entity 'plasma' named entity 'viral entry' named entity 'Influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software